&gt; Without more information, I think the indignant tone and format of this article are unwarranted.<p>Agreed. For me, that &quot;more information&quot; includes things like: whether or not the drug is viable at its former price, the likelihood of this price driving other entrants into the market to find new solutions to address this problem, the ability of other manufacturers to develop substitutes, the amount of the profits that will be returned into development of other drugs that will save other lives, the baseline cost per life saved across the pharmaceutical industry, et. al.<p>High prices attract attention to existing social problems and are sometimes useful. Other times they&#x27;re opportunistic and exploitative. It&#x27;s not trivial to isolate the two.